After three years of COVID-19 disruptions of varying levels of seriousness, as it stood in fall 2022, the hope was that 2023 could ̶ should ̶ be a period of more stable market conditions for medtechs.
With the pandemic, however, it seems nothing is certain. New US COVID-19 infection rates were still doggedly above a quarter...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?